Higher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022
touchCONGRESS for touchONCOLOGY
Listen to Dr Esther Oliva (Italy) review key data presented at the EHA 2022 Hybrid Congress on recent developments in the treatment of higher-risk MDS and newly diagnosed AML; she offers her expert insights on their potential impact on future clinical practice, alongside those from Prof. Michael Heuser (Germany) and Dr Yishai Ofran (Israel).
OVERVIEW
INTERVIEW QUESTIONS
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/MDS-AML-EHA2022-touchcongress/
Create your
podcast in
minutes
It is Free